Reshma Kewalramani, CEO & President at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 99 shares at $282.74 ($28K) on 2020-05-15, disclosed to the SEC on 2020-05-19.
Scheduled sale ($28k) by CEO & President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $274.37 | 2 | $549 | 2.0% |
| 2 | $276.40 | 6 | $2K | 5.9% |
| 3 | $279.70 | 7 | $2K | 7.0% |
| 4 | $280.47 | 9 | $3K | 9.0% |
| 5 | $281.74 | 6 | $2K | 6.0% |
| 6 | $282.74 | 4 |
| $1K |
| 4.0% |
| 7 | $283.76 | 10 | $3K | 10.1% |
| 8 | $286.07 | 27 | $8K | 27.5% |
| 9 | $287.63 | 19 | $5K | 19.4% |
| 10 | $288.37 | 9 | $3K | 9.2% |
| Total | $284.17 avg | 99 | $28K | 100% |
| Filing → |
| VRTX | SELL | 2024-11-12 | $7.8M | — | Filing → |
| VRTX | SELL | 2024-08-01 | $7.7M | — | Filing → |
| VRTX | SELL | 2024-07-24 | $7.6M | — | Filing → |